Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

181. Harnessing the Question-Behavior Effect to Enhance Colorectal Cancer Screening in an mHealth Experiment

Harnessing the Question-Behavior Effect to Enhance Colorectal Cancer Screening in an mHealth Experiment 27631750 2016 09 15 2016 10 07 1541-0048 106 11 2016 Nov American journal of public health Am J Public Health Harnessing the Question-Behavior Effect to Enhance Colorectal Cancer Screening in an mHealth Experiment. 1998-2004 To assess whether asking questions about a future behavior changes this behavior (i.e., the question-behavior effect) when applied to a population-level intervention (...) to enhance colorectal cancer screening. In 2013, text-message reminders were sent to a national sample of 50 000 Israeli women and men aged 50 to 74 years following a fecal occult blood test invitation. Participants were randomized into 4 intervention groups (2 interrogative reminders, with or without reference to social context; 2 noninterrogative reminders, with or without social context) and a no-intervention control group. The outcome was fecal occult blood test uptake (n = 48 091, following

EvidenceUpdates2016

182. [Ramucirumab (colorectal cancer)]

[Ramucirumab (colorectal cancer)] Ramucirumab (kolorektalkarzinom): addendum zum auftrag A16-10; auftrag A16-50 [Ramucirumab (colorectal cancer) - addendum to commission A16-10] Ramucirumab (kolorektalkarzinom): addendum zum auftrag A16-10; auftrag A16-50 [Ramucirumab (colorectal cancer) - addendum to commission A16-10] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Ramucirumab (kolorektalkarzinom): addendum zum auftrag A16-10; auftrag A16-50. [Ramucirumab (colorectal cancer) - addendum to commission A16-10] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 412. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH

Health Technology Assessment (HTA) Database.2016

183. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial 27660192 2016 09 23 2016 11 07 1474-5488 17 11 2016 Nov The Lancet. Oncology Lancet Oncol. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. 1543-1557 S1470-2045(16)30172-3 10.1016/S1470-2045(16)30172-3 Antiangiogenic agents have established (...) efficacy in the treatment of metastatic colorectal cancer. We investigated whether bevacizumab could improve disease-free survival in the adjuvant setting after resection of the primary tumour. For the open-label, randomised, controlled QUASAR 2 trial, which was done at 170 hospitals in seven countries, we recruited patients aged 18 years or older with WHO performance status scores of 0 or 1 who had undergone potentially curative surgery for histologically proven stage III or high-risk stage II

EvidenceUpdates2016

184. Colorectal cancer incidence in 5 Asian countries by subsite: An analysis of Cancer Incidence in Five Continents (1998-2007)

Colorectal cancer incidence in 5 Asian countries by subsite: An analysis of Cancer Incidence in Five Continents (1998-2007) WHO IRIS: Colorectal cancer incidence in 5 Asian countries by subsite: An analysis of Cancer Incidence in Five Continents (1998-2007) Browse Related links Files in This Item: No electronic version is available yet. Title: Colorectal cancer incidence in 5 Asian countries by subsite: An analysis of Cancer Incidence in Five Continents (1998-2007) Authors: Issue Date: 4-Oct (...) -2016 Language: English Abstract: Colorectal cancer is the fourth most common cancer in Asia. However, the trends in colorectal cancer incidence by subsite have not been analyzed across Asian countries. We used the most recent, high quality data from 6 cancer registries for two 5-year periods, 1998-2002 and 2003-2007, from Cancer Incidence in Five Continents to estimate colorectal cancer incidence by subsite in 5 Asian countries. Cases with overlapping lesions or otherwise unspecified colon cancer

WHO2016

185. Self-Expandable Metal Stents for Colorectal Cancer: From Guidelines to Clinical Practice

Self-Expandable Metal Stents for Colorectal Cancer: From Guidelines to Clinical Practice 28868482 2018 11 13 2341-4545 23 6 2016 Nov-Dec GE Portuguese journal of gastroenterology GE Port J Gastroenterol Self-Expandable Metal Stents for Colorectal Cancer: From Guidelines to Clinical Practice. 293-299 10.1016/j.jpge.2016.06.003 Colonic self-expandable metal stent placement is widely used for palliation of obstructive colorectal cancer. The European recommendations for stent placement as a bridge (...) to elective surgery in obstructive colorectal cancer were recently reviewed. The aim of this study was to evaluate the efficacy and safety of stent placement in obstructive colorectal cancer and to discuss these recent guidelines. Demographic characteristics, procedure indications, complications and final outcome in patients with obstructive colorectal cancer who underwent endoscopic stent placement between January 2012 and June 2015 were retrospectively analyzed. Statistical analysis was performed

GE Portuguese journal of gastroenterology2016 Full Text: Link to full Text with Trip Pro

187. Effectiveness of Screening Colonoscopy to Prevent Colorectal Cancer Among Medicare Beneficiaries Aged 70 to 79 Years: A Prospective Observational Study.

Effectiveness of Screening Colonoscopy to Prevent Colorectal Cancer Among Medicare Beneficiaries Aged 70 to 79 Years: A Prospective Observational Study. Background: No randomized, controlled trials of screening colonoscopy have been completed, and ongoing trials exclude persons aged 75 years or older. The Medicare program, however, reimburses screening colonoscopy without an upper age limit. Objective: To evaluate the effectiveness and safety of screening colonoscopy to prevent colorectal (...) cancer (CRC) in persons aged 70 to 74 and those aged 75 to 79 years. Design: Large-scale, population-based, prospective study. The observational data were used to emulate a target trial with 2 groups: colonoscopy screening and no screening. Setting: United States. Participants: 1 355 692 Medicare beneficiaries (2004 to 2012) aged 70 to 79 years at average risk for CRC who used Medicare preventive services and had no previous diagnostic or surveillance colonoscopies in the past 5 years. Measurements

Annals of Internal Medicine2016 Full Text: Link to full Text with Trip Pro

188. Blood Measurement of Carcinoembryonic Antigen Level for Detecting Recurrence of Colorectal Cancer.

Blood Measurement of Carcinoembryonic Antigen Level for Detecting Recurrence of Colorectal Cancer. CLINICAL QUESTION: What is the trade-off between sensitivity and specificity at specific carcinoembryonic antigen (CEA) thresholds for detecting recurrent colorectal cancer? BOTTOM LINE: To detect colorectal cancer recurrence, the sensitivity of CEA ranges from 68% for a threshold of 10 µg/L to 82% for a threshold of 2.5 µg/L and the specificity ranges from 97% for a threshold of 10 µg/L to 80

JAMA2016

192. Trifluridine-tipiracil for previously treated metastatic colorectal cancer

Trifluridine-tipiracil for previously treated metastatic colorectal cancer T T rifluridine–tipir rifluridine–tipiracil for pre acil for previously viously treated metastatic colorectal cancer treated metastatic colorectal cancer T echnology appraisal guidance Published: 24 August 2016 nice.org.uk/guidance/ta405 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

National Institute for Health and Clinical Excellence - Technology Appraisals2016

193. Screening for colorectal cancer: effect on health outcomes

Screening for colorectal cancer: effect on health outcomes Screening for colorectal cancer: effect on health outcomes - Nasjonalt kunnskapssenter for helsetjenesten Main menu Menu The Knowledge Centre for the Health Services is part of the Norwegian Institute of Public Health since January 1, 2016. For new publications, please go to Search Rapport fra Folkehelseinstituttet - Hurtigoversikt Screening for colorectal cancer: effect on health outcomes Published 06/09/2016 Fretheim A, Reinar LM (...) , Bretthauer M. Screening for colorectal cancer: effect on health outcomes. Rapport fra Folkehelseinstituttet – 2016. ISBN 978-82-8082-758-6 Key messages There are ongoing discussions about whether to implement a national screening program for colorectal cancer in Norway. On request from the Norwegian Directorate for Health, The Knowledge Centre at the Norwegian Institute of Public Health has prepared a summary of the current evidence base regarding health effects of this type of screening. We found

The Norwegian Knowledge Centre for the Health Services2016

194. A randomised comparison of two faecal immunochemical tests in population-based colorectal cancer screening

A randomised comparison of two faecal immunochemical tests in population-based colorectal cancer screening 27507905 2016 08 10 2016 08 10 1468-3288 2016 Aug 09 Gut Gut A randomised comparison of two faecal immunochemical tests in population-based colorectal cancer screening. gutjnl-2016-311819 10.1136/gutjnl-2016-311819 Colorectal cancer screening programmes are implemented worldwide; many are based on faecal immunochemical testing (FIT). The aim of this study was to evaluate two frequently (...) . Dekker E E Department of Gastroenterology and Hepatology, Academic Medical Centre Amsterdam, Amsterdam, The Netherlands. Spaander M C W MC Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands. eng Journal Article 2016 08 09 England Gut 2985108R 0017-5749 COLORECTAL CANCER SCREENING COLORECTAL CARCINOMA 2016 03 08 2016 07 06 2016 8 11 6 0 2016 8 11 6 0 2016 8 11 6 0 aheadofprint 27507905 gutjnl-2016-311819 10.1136/gutjnl-2016-311819

EvidenceUpdates2016

195. Full-spectrum (FUSE) versus standard forward-viewing colonoscopy in an organised colorectal cancer screening programme

Full-spectrum (FUSE) versus standard forward-viewing colonoscopy in an organised colorectal cancer screening programme 27507903 2016 08 10 2016 08 10 1468-3288 2016 Aug 09 Gut Gut Full-spectrum (FUSE) versus standard forward-viewing colonoscopy in an organised colorectal cancer screening programme. gutjnl-2016-311906 10.1136/gutjnl-2016-311906 Miss rate of polyps has been shown to be substantially lower with full-spectrum endoscopy (FUSE) compared with standard forward-viewing (SFV) colonoscopy (...) in a tandem study at per polyp analysis. However, there is uncertainty on whether FUSE is also associated with a higher detection rate of colorectal neoplasia, especially advanced lesions, in per patient analysis. Consecutive subjects undergoing colonoscopy following a positive faecal immunochemical test (FIT) by experienced endoscopists and performed in the context of a regional colorectal cancer population-screening programme were randomised between colonoscopy with either FUSE or SFV colonoscopy

EvidenceUpdates2016

196. Financial Incentives for Promoting Colorectal Cancer Screening: A Randomized, Comparative Effectiveness Trial

Financial Incentives for Promoting Colorectal Cancer Screening: A Randomized, Comparative Effectiveness Trial 27481306 2016 08 02 2017 02 20 1572-0241 111 11 2016 Nov The American journal of gastroenterology Am. J. Gastroenterol. Financial Incentives for Promoting Colorectal Cancer Screening: A Randomized, Comparative Effectiveness Trial. 1630-1636 10.1038/ajg.2016.286 Offering financial incentives to promote or "nudge" participation in cancer screening programs, particularly among vulnerable (...) populations who traditionally have lower rates of screening, has been suggested as a strategy to enhance screening uptake. However, effectiveness of such practices has not been established. Our aim was to determine whether offering small financial incentives would increase colorectal cancer (CRC) screening completion in a low-income, uninsured population. We conducted a randomized, comparative effectiveness trial among primary care patients, aged 50-64 years, not up-to-date with CRC screening served

EvidenceUpdates2016

197. Colorectal Cancer on the Decline.

Colorectal Cancer on the Decline. Colorectal Cancer on the Decline. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27557317 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 25;375(8):804. doi: 10.1056/NEJMc1608037. Colorectal Cancer on the Decline. , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27557317 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You are here

NEJM2016

198. Colorectal Cancer on the Decline.

Colorectal Cancer on the Decline. Colorectal Cancer on the Decline. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27557318 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 25;375(8):803. doi: 10.1056/NEJMc1608037#SA1. Colorectal Cancer on the Decline. 1 , 2 , 3 . 1 New York Medical College, Valhalla, NY lowenfel@nymc.edu. 2 European Institute of Oncology, Milan, Italy. 3 Weill Cornell Medical College in Qatar, Doha, Qatar. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27557318 DOI: [Indexed for MEDLINE

NEJM2016 Full Text: Link to full Text with Trip Pro

199. Colorectal Cancer on the Decline.

Colorectal Cancer on the Decline. Colorectal Cancer on the Decline. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27557319 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 25;375(8):804. doi: 10.1056/NEJMc1608037#SA2. Colorectal Cancer on the Decline. 1 . 1 Paris-Diderot University, Paris, France claude.matuchansky@wanadoo.fr. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27557319 DOI: [Indexed for MEDLINE] Publication types MeSH terms Full Text Sources Medical PubMed Commons 0 comments How to cite this comment

NEJM2016 Full Text: Link to full Text with Trip Pro

200. DNA Repair Defect and RAS Mutation in Two Patients With Schistosoma mansoni–Associated Colorectal Cancer: Carcinogenesis Steps or Mere Coincidence?

DNA Repair Defect and RAS Mutation in Two Patients With Schistosoma mansoni–Associated Colorectal Cancer: Carcinogenesis Steps or Mere Coincidence? 28831451 2018 11 13 2378-9506 3 4 2017 Aug Journal of global oncology J Glob Oncol DNA Repair Defect and RAS Mutation in Two Patients With Schistosoma mansoni -Associated Colorectal Cancer: Carcinogenesis Steps or Mere Coincidence? 423-426 10.1200/JGO.2016.006254 Almeida Gustavo Fernandes Godoy GFG , , , , , and , Hospital das Clinicas Federal (...) -74 21376230 World J Surg Oncol. 2010 Aug 13;8:68 20704754 Dig Endosc. 2010 Apr;22(2):133-6 20447208 Lancet. 2014 Jun 28;383(9936):2253-64 24698483 Cancer Lett. 1998 Sep 25;131(2):215-21 9851256 Int J Immunopathol Pharmacol. 2006 Jan-Mar;19(1):245-6 16569365 Prostaglandins Leukot Essent Fatty Acids. 2015 Apr;95:57-62 25687497 Asian Pac J Cancer Prev. 2002;3(4):361-366 12716295 Clin Microbiol Rev. 1999 Jan;12(1):97-111 9880476 Cell Oncol. 2005;27(4):245-53 16308474 Asian Pac J Cancer Prev. 2013;14

Journal of global oncology2016 Full Text: Link to full Text with Trip Pro